Skip to main content

Table 2 Overall mortality of the study patients compared to that of the male population of Finland

From: Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation

All patientsPeriod
1985–19941995–20042005–2014
ADTObservationADTObservationADTObservation
AgeSMR (95% confidence interval)
All (> 70)1.48 (1.41–1.54)1.20 (1.10–1.30)1.19 (1.15–1.23)1.03 (0.98–1.08)1.08 (1.03–1.13)0.93 (0.88–0.98)
70–791.57 (1.48–1.65)1.17 (1.05–1.30)1.24 (1.19–1.29)1.05 (0.99–1.11)1.11 (1.04–1.19)0.95 (0.88–1.01)
≥801.39 (1.22–1.42)1.25 (1.08–1.43)1.10 (1.04–1.17)1.00 (0.92–1.09)1.04 (0.97–1.11)0.89 (0.82–0.97)
Matched pairs
 All (> 70)1.50 (1.38–1.63)1.19 (1.09–1.30)1.19 (1.13–1.25)1.03 (0.98–1.08)1.09 (1.03–1.15)0.93 (0.87–0.98)
 70–791.57 (1.41–1.74)1.16 (1.04–1.29)1.23 (1.16–1.30)1.05 (0.99–1.11)1.12 (1.05–1.20)0.94 (0.87–1.01)
  ≥ 801.39 (1.21–1.60)1.25 (1.08–1.44)1.12 (1.02–1.21)1.00 (0.91–1.08)1.03 (0.94–1.12)0.91 (0.82–0.99)
  1. Population mortality stratified by age and calendar year and education level
  2. ADT androgen deprivation therapy, SMR standardized mortality ratio